QQQ   312.83 (-3.49%)
AAPL   120.99 (-3.48%)
MSFT   228.99 (-2.37%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   682.22 (-8.06%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.21 (-6.71%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.42 (-5.20%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
QQQ   312.83 (-3.49%)
AAPL   120.99 (-3.48%)
MSFT   228.99 (-2.37%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   682.22 (-8.06%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.21 (-6.71%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.42 (-5.20%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
QQQ   312.83 (-3.49%)
AAPL   120.99 (-3.48%)
MSFT   228.99 (-2.37%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   682.22 (-8.06%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.21 (-6.71%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.42 (-5.20%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
QQQ   312.83 (-3.49%)
AAPL   120.99 (-3.48%)
MSFT   228.99 (-2.37%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   682.22 (-8.06%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.21 (-6.71%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.42 (-5.20%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
Log in
NASDAQ:IONS

Ionis Pharmaceuticals Stock Forecast, Price & News

$53.41
-2.80 (-4.98 %)
(As of 02/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$52.94
Now: $53.41
$56.02
50-Day Range
$55.94
MA: $59.73
$63.78
52-Week Range
$39.32
Now: $53.41
$64.37
Volume1.15 million shs
Average Volume895,348 shs
Market Capitalization$7.47 billion
P/E Ratio111.27
Dividend YieldN/A
Beta1.42
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic from ALS; ION859 for Parkinson's disease; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing severe and rare disease products, such as AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-PKK-LRx for hereditary angioedema; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-ENAC-2.5Rx for cystic fibrosis; and ION357 for retinitis pigmentosa. In addition, its cardio metabolic and renal drugs include AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases; AKCEA-ANGPTL3-LRx for cardio metabolic disorders; IONIS-GCGRRx for type 2 diabetes; IONIS-AGT-LRX for the treatment of resistant hyper tension; IONIS-FXI-LRx for clotting disorders; IONIS-AZ4-2.5-LRx for cardiovascular diseases; and ION839 for nonalcoholic steatohepatitis. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; IONIS-HBVRx and IONIS-HBV-LRx for hepatitis B virus infection; and IONIS-FB-LRx for compliment meditated disease. It has a collaboration agreement with AstraZeneca; Biogen Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Ionis Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:IONS
CUSIP46433010
Phone760-931-9200
Employees817
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.12 billion
Cash Flow$2.18 per share
Book Value$11.98 per share

Profitability

Net Income$303.26 million

Miscellaneous

Market Cap$7.47 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.22 out of 5 stars

Medical Sector

972nd out of 1,957 stocks

Pharmaceutical Preparations Industry

461st out of 771 stocks

Analyst Opinion: 2.1Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$53.41
-2.80 (-4.98 %)
(As of 02/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IONS News and Ratings via Email

Sign-up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions

Is Ionis Pharmaceuticals a buy right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Ionis Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares.
View analyst ratings for Ionis Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Ionis Pharmaceuticals?

Wall Street analysts have given Ionis Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ionis Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Ionis Pharmaceuticals' next earnings date?

Ionis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Ionis Pharmaceuticals
.

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) posted its quarterly earnings data on Wednesday, February, 24th. The company reported ($2.44) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.24 by $2.68. Ionis Pharmaceuticals had a net margin of 7.82% and a trailing twelve-month return on equity of 6.57%.
View Ionis Pharmaceuticals' earnings history
.

How has Ionis Pharmaceuticals' stock price been impacted by COVID-19?

Ionis Pharmaceuticals' stock was trading at $49.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IONS shares have increased by 8.7% and is now trading at $53.41.
View which stocks have been most impacted by COVID-19
.

What guidance has Ionis Pharmaceuticals issued on next quarter's earnings?

Ionis Pharmaceuticals updated its FY 2021 Pre-Market earnings guidance on Wednesday, February, 24th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $600 million, compared to the consensus revenue estimate of $781.31 million.

What price target have analysts set for IONS?

13 Wall Street analysts have issued 12 month price targets for Ionis Pharmaceuticals' shares. Their forecasts range from $34.00 to $91.00. On average, they anticipate Ionis Pharmaceuticals' share price to reach $61.90 in the next year. This suggests a possible upside of 15.9% from the stock's current price.
View analysts' price targets for Ionis Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Ionis Pharmaceuticals' key executives?

Ionis Pharmaceuticals' management team includes the following people:
  • Dr. Stanley T. Crooke, Founder & Exec. Chairman (Age 76, Pay $1.97M)
  • Dr. Brett P. Monia, Founder, CEO & Director (Age 60, Pay $1.06M)
  • Ms. Elizabeth L. Hougen, Exec. VP of Fin. & CFO (Age 59, Pay $834.19k)
  • Mr. Patrick R. O'Neil, Exec. VP of Legal, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 47, Pay $816.23k)
  • Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 67, Pay $1.36M)
  • Dr. Richard S. Geary, Exec. VP & Chief Devel. Officer (Age 63, Pay $829.79k)
  • Mr. Darren Gonzales, Chief Accounting Officer & Sr. VP
  • Dr. C. Frank Bennett, Exec. VP & Chief Scientific Officer (Age 64)
  • Mr. D. Wade Walke, VP of Investor Relations
  • Ms. Roslyn Patterson M.B.A., VP of Marketing & Communications

Who are some of Ionis Pharmaceuticals' key competitors?

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (14.97%), Price T Rowe Associates Inc. MD (9.38%), Clearbridge Investments LLC (4.95%), JPMorgan Chase & Co. (1.34%), First Trust Advisors LP (0.99%) and Northern Trust Corp (0.59%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke.
View institutional ownership trends for Ionis Pharmaceuticals
.

Which major investors are selling Ionis Pharmaceuticals stock?

IONS stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Renaissance Technologies LLC, Clearbridge Investments LLC, Dowling & Yahnke LLC, Sei Investments Co., AJO LP, Pinnacle Associates Ltd., and Hsbc Holdings PLC. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen, and Stanley T Crooke.
View insider buying and selling activity for Ionis Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Ionis Pharmaceuticals stock?

IONS stock was acquired by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, JPMorgan Chase & Co., PFM Health Sciences LP, Morgan Stanley, Alyeska Investment Group L.P., Alyeska Investment Group L.P., Nuveen Asset Management LLC, and Nikko Asset Management Americas Inc..
View insider buying and selling activity for Ionis Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ionis Pharmaceuticals' stock price today?

One share of IONS stock can currently be purchased for approximately $53.41.

How much money does Ionis Pharmaceuticals make?

Ionis Pharmaceuticals has a market capitalization of $7.47 billion and generates $1.12 billion in revenue each year. The company earns $303.26 million in net income (profit) each year or $2.08 on an earnings per share basis.

How many employees does Ionis Pharmaceuticals have?

Ionis Pharmaceuticals employs 817 workers across the globe.

What is Ionis Pharmaceuticals' official website?

The official website for Ionis Pharmaceuticals is www.ionispharma.com.

Where are Ionis Pharmaceuticals' headquarters?

Ionis Pharmaceuticals is headquartered at 2855 GAZELLE COURT, CARLSBAD CA, 92010.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200 or via email at [email protected]


This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.